|
CLNN | Clene Inc. |
|
|
CLNN | Clene Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ -0.01 |
| Leverage | 155.39% |
| Market Cap | $ 827.0m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -30.3m |
| Margin | 2728.04% |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.